Trametinib (Mekinist) - Uses, Dose, Side effects

Trametinib (Mekinist) is a MEK 1 and MEK 2 inhibitor. It stops the growth and spread of the tumor cells in patients with melanoma, lung, and thyroid cancers.

Indications of Trametinib (Mekinist):

  • Melanoma:

    • It is used in combination with dabrafenib in patients with BRAF V600E or BRAF V600K mutations, lymph node involvement, following complete resection OR
    • The treatment of unresectable or metastatic melanoma in patients as a single agent or combination therapy.
  • Metastatic Non-small cell lung cancer:

    • It is indicated as combination therapy for the treatment of metastatic non-small cell lung cancer in patients with BRAF V600E mutation.
  • Locally advanced or metastatic anaplastic thyroid cancer:

    • It is used in combination for treating locally advanced or metastatic anaplastic thyroid malignancy with BRAF V600E mutation and with no satisfactory locoregional treatment options.

Trametinib (Mekinist) dose Adults

Note: BRAF V600 mutation status should be verified before treatment.

Trametinib (Mekinist) dose for the treatment Melanoma as adjuvant therapy (with BRAF V600E or BRAF V600K mutations):

  • 2 mg  per oral once daily (in combination with dabrafenib);
  • continue for ≤1 year in the absence of disease progression or unacceptable toxicity.

Trametinib (Mekinist) dose for the treatment of metastatic or unresectable Melanoma (with BRAF V600E or BRAF V600K mutations):

  • 2 mg per oral once daily (monotherapy or in combination with dabrafenib),
  • continue until disease progression or unacceptable toxicity.

Trametinib (Mekinist) dose for the treatment of metastatic Non-small cell lung cancer (with BRAF V600E mutation):

  • 2 mg per oral once daily (in combination with dabrafenib);
  • continue until disease progression or unacceptable toxicity.

Trametinib (Mekinist) dose for the treatment of locally advanced or metastatic Anaplastic Thyroid cancer (with BRAF V600E mutation):

  • 2 mg per oral once daily (in combination with dabrafenib); continue until disease progression or unacceptable toxicity.

Missed doses:

  • Do not take a missed dose within 12 hours of the next dose.

FDA prescribing information is available in PDF.

Use in Children:

The safety and efficacy of the drug in children have not been established.

Pregnancy Risk Category D

  • Studies on animal reproduction showed that fetal harm was evident.
  • Effective contraceptives should be used by both males and females with reproductive potential during trametinib treatment and for at least 4 months following the last trametinib dosage.

Use while breastfeeding

  • It is not known if Trametinib is excreted in breast milk.
  • Due to serious side effects, the manufacturer does not recommend breastfeeding during trametinib therapy or for at least 4 months after the last dose.

Trametinib (Mekinist) Dose adjustment in renal disease:

  • Mild to moderate impairment (GFR ≥30 mL/minute/1.73 m²):

    • No dosage adjustment necessary.
  • Severe impairment (GFR <30 mL/minute/1.73 m²):

    • There are no dosage adjustments provided in the manufacturer's labeling.

Trametinib (Mekinist) Dose adjustment in liver disease:

  • Mild impairment bilirubin ≤ upper normal limit and AST > upper normal limit or bilirubin >1 to 1.5 times upper normal limit with any AST:

    • No dosage adjustment necessary.
  • Moderate bilirubin >1.5 to 3 times upper normal limit and any AST to severe bilirubin >3 to 10 times upper normal limit and any AST impairment:

    • There are no dosage adjustments provided in the manufacturer's labeling (an appropriate dose has not been established).

Common Side Effects of Trametinib (Mekinist) monotherapy:

  • Cardiovascular:

    • Hypertension
    • Cardiomyopathy
  • Dermatologic:

    • Skin Toxicity
    • Skin Rash
    • Acneiform Eruption
    • Xeroderma
  • Endocrine & Metabolic:

    • Hypoalbuminemia
  • Gastrointestinal:

    • Diarrhea
    • Stomatitis
    • Abdominal Pain
  • Hematologic & Oncologic:

    • Anemia
    • Lymphedema
    • Hemorrhage
  • Hepatic:

    • Increased Serum Aspartate Aminotransferase
    • Increased Serum Alanine Aminotransferase
    • Increased Serum Alkaline Phosphatase

Rare Side Effects of Trametinib (Mekinist):

  • Cardiovascular:

    • Decreased Left Ventricular Ejection Fraction
    • Bradycardia
  • Central Nervous System:

    • Dizziness
  • Dermatologic:

    • Paronychia
    • Pruritus
    • Cellulitis
    • Folliculitis
    • Pustular Rash
  • Gastrointestinal:

    • Dysgeusia
    • Xerostomia
  • Neuromuscular & Skeletal:

    • Rhabdomyolysis
  • Ophthalmic:

    • Blurred Vision
    • Dry Eye Syndrome
  • Respiratory:

    • Interstitial Pulmonary Disease
    • Pneumonitis

Side effects reported with dual therapy (trametinib plus dabrafenib):

Common Side Effects of Trametinib (Mekinist):

  • Cardiovascular:

    • Hypertension
    • Peripheral Edema
    • Prolonged Q-T Interval On ECG
  • Central Nervous System:

    • Fatigue
    • Headache
    • Chills
    • Dizziness
  • Dermatologic:

    • Skin Toxicity
    • Skin Rash
    • Xeroderma
  • Endocrine & Metabolic:

    • Hyperglycemia
    • Hyponatremia
    • Hypoalbuminemia
    • Hypophosphatemia
    • Exacerbation Of Diabetes Mellitus
  • Gastrointestinal:

    • Nausea
    • Vomiting
    • Diarrhea
    • Decreased Appetite
    • Abdominal Pain
    • Constipation
  • Hematologic & Oncologic:

    • Neutropenia
    • Leukopenia
    • Anemia
    • Lymphocytopenia
    • Hemorrhage
    • Thrombocytopenia
    • Malignant Neoplasm
  • Hepatic:

    • Increased Serum Alkaline Phosphatase
    • Increased Serum Aspartate Aminotransferase
    • Increased Serum Alanine Aminotransferase
  • Neuromuscular & Skeletal:

    • Arthralgia
    • Myalgia
  • Renal:

    • Increased Serum Creatinine
  • Respiratory:

    • Cough
    • Dyspnea
  • Miscellaneous:

    • Fever
    • Febrile Reaction

Rare Side Effects of Trametinib (Mekinist) (dual therapy):

  • Cardiovascular:

    • Bradycardia
    • Cardiomyopathy
    • Reduced Ejection Fraction
    • Venous Thromboembolism
    • Hypertension
  • Central Nervous System:

    • Intracranial Hemorrhage
  • Gastrointestinal:

    • Gastrointestinal Hemorrhage
    • Pancreatitis
  • Hematologic & Oncologic:

    • Basal Cell Carcinoma
    • Squamous Cell Carcinoma Of Skin
  • Neuromuscular & Skeletal:

    • Rhabdomyolysis
  • Ophthalmic:

    • Blurred Vision
  • Respiratory:

    • Pneumonitis

Contraindication to Trametinib (Mekinist):

The US labeling of the manufacturer does not list any contraindications. Canadian labeling: Hypersensitivity of trametinib and any component of the formulation.

Warnings and precautions

  • Suppression of bone marrow

    • When taken concurrently with dabrafenib, it can cause neutropenia.
  • Cardiac events

    • This can lead to heart failure, or decreased left ventricular ejection percentage. Therefore, an echocardiogram and MUGA scan are required at regular intervals.
    • In severe cases, it may be necessary to reduce or stop the dose.
  • Dermatologic toxicities:

    • In severe cases, drug therapy should be stopped.
  • Febrile reactions

    • Combining trametinib with dabrafenib can cause fever, hypotension, rigors/chills or renal failure.
    • If the fever persists for more than 3 days or complications occur, corticosteroids are recommended.
  • Events in the gastrointestinal tract:

    • It can lead to life-threatening colitis or GI perforation.
  • Hemorrhage

    • Drug therapy can lead to fatal intracranial, retroperitoneal, and gastrointestinal hemorhages.
  • Hepatotoxicity

    • Trametinib has been linked to liver dysfunction.
  • Hyperglycemia

    • Combination therapy with trametinib/dabrafenib may cause hyperglycemia. Therefore, glucose monitoring or insulin therapy may be necessary.
  • Hypertension

    • You should use it with caution as hypertension can result.
  • Malignancy

    • Basal cell carcinoma and cutaneous squamous cells carcinoma can both be detected in single-agent therapy or dual therapy.
    • Dermatological exams should be done before treatment begins, every 2 months, during treatment, and up to 6 months after discontinuation.
  • Ocular toxicities:

    • There are two possible outcomes: retinal vein occlusion and retinal pigment epithelial dissociation (RPED).
    • These can lead to macular edema, reduced visual function, neovascularization and glaucoma.
    • If a retinal vein occlusion occurs, the drug should immediately be stopped
    • If iritis or uveitis occurs, it should be treated immediately with mydriatic drops and ophthalmic steroids.
  • Toxicity in the lungs:

    • Pneumonitis and interstitial lung disease can present with symptoms such as cough, dyspnea or hypoxia.
  • Venous thromboembolism

    • You should be aware that it can lead to pulmonary embolism and fatal deep vein thrombosis.

Trametinib: Drug Interaction

Risk Factor C (Monitor therapy)

Dabrafenib

Trametinib may enhance the adverse/toxic effect of Dabrafenib.

Monitoring parameters:

  • Blood glucose
  • LFTs
  • Echo and MUGA scan to assess LVF status
  • BRAF V600K or V600E mutation status before treatment
  • Pregnancy
  • Ophthalmic exam
  • Signs/symptoms of pulmonary/dermatological toxicity.
  • Signs/symptoms of infection
  • Signs/symptoms of cutaneous and noncutaneous malignancies

How to administer Trametinib (Mekinist):

  • It should be taken orally at least one hour before or two hours after a meal.
  • Dosage should be taken at the same time every day.
  • Trametinib should not be given more than once a day.

Mechanism of action of Trametinib (Mekinist):

  • Trametinib selectively inhibits mitogen-activated ex kinase 1 and 2 activation, kinase activity, leading to decreased cell proliferation, cell cycle arrest and increased apoptosis.
  • Combining trametinib with dabrafenib causes MAPK pathway inhibition at a greater scale.
  • This results in BRAF V600 melanoma cells dying. Combining dabrafenib with Trametinib results in synergistic inhibitions of cell growth in lung carcinoma cell lines that are BRAF V600E mutation.

Absorption:

  • Rapid; decreased with a high-fat, high-calorie meal (1,000 calories)

Distribution:

  • 214 L

Protein binding:

  • 97% to plasma proteins

Metabolism:

  • Predominantly deacetylation (via hydrolytic enzymes) alone or with monooxygenation or in combination with glucuronidation

Bioavailability:

  • 72%

Half-life elimination:

  • 4 to 5 days

Time to peak:

  • 1.5 hours; delayed with a high-fat, high-calorie meal (1,000 calories)

Excretion:

  • Feces (>80%)
  • urine (<20% with <0.1% as unchanged drug)

International Brands of Trametinib:

  • Mekinist

Trametinib Brand Names in Pakistan:

No Brands Available in Pakistan.

Comments

NO Comments Found